Evidence map›Paper›PMID 37116132›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2023

Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.

Dyah Aryani Perwitasari, Fredrick Dermawan Purba, Susan Fitria Candradewi, Marwin Marwin, Agung Permata, Muhammad Barik Ulfa Faza, Bayu Priyo Septiantoro, Adrian A Kaptein

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dyah Aryani PerwitasariFaculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.
Fredrick Dermawan PurbaFaculty of Psychology, Universitas Padjadjaran, Sumedang, Jawa Barat, Indonesia.ORCID 0000-0002-7336-3043
Susan Fitria CandradewiFaculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.ORCID 0000-0003-3560-398X
Marwin MarwinFaculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.
Agung PermataDepartment of Clinical Pharmacy and Community, Institute of Technology, Science and Health, Dr Soepraoen Hospital, Malang, East of Java, Indonesia.
Muhammad Barik Ulfa FazaFarmaza Pharmacy, Demak, Centre of Java, Indonesia.
Bayu Priyo SeptiantoroKaryadi Hospital, Semarang, Indonesia.
Adrian A KapteinLeiden University Medical Centre, Netherlands.ORCID 0000-0002-1333-7679

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to develop a mapping algorithm for EORTC QLQ-C30 to EQ-5D-5L which can produce utility values in patients with cancer.

methodsWe used a cross sectional study design with 300 cancer patients. The research instruments used were EORTC QLQ-C30 and EQ-5D-5L. Data were collected by interviewing cancer patients who were hospitalized in the Kasuari Installation of Dr Kariadi Hospital Semarang, Indonesia. The Ordinary Least Squares (OLS) regression method was used to predict the utility value of EQ-5D-5L. This study uses two models to predict utility values, namely model 1 with all domains, and model 2 with domains that affect the EQ-5D-5L. The predictive power of regression on the model is evaluated by calculating the mean absolute error (MAE) and root mean square error (RMSE) values.

resultThe highest score in the functional domain is the 'emotional function' domain (mean: 85.89; SD: 16.04) and the highest symptom domain is 'weakness' (mean: 36.21; SD:21.69). The predicted utility values of models 1 and 2 are 0.683. The mean absolute error (MAE) and root mean square error (RMSE) values of model 1 are 0.128 and 0.173, while in model 2 the MAE and RMSE values obtained are 0.125 and 0.168.

conclusionThe development of the mapping algorithm from the EORTC QLQ-C30 to EQ-5D-5L instrument shows a predictive value of utility in a sample of patients with cancer at Dr. Kariadi Hospital, Semarang, Indonesia. The utility prediction in both model is similar, however model 2 involves fewer domains and symptoms.<br />.

Indexed as

NeoplasmsQuality of LifeAlgorithmsCross-Sectional StudiesHumansIndonesiaSurveys and QuestionnairescancerEORTC-QLQ-C30EQ-5D-5LMappingUtility

Identifiers

PMID37116132
PMCPMC10352743

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.